<DOC>
	<DOCNO>NCT01763645</DOCNO>
	<brief_summary>BCD-021-02 double-blind randomize clinical trial compare efficacy BCD-021 ( INN : bevacizumab ) paclitaxel + carboplatin Avastin paclitaxel + carboplatin inoperable advanced non-squamous NSCLC patient pharmacokinetics substudy . The purpose study demonstrate non-inferiority efficacy safety BCD-021 compare Avastin . Also study include pharmacokinetics assessment .</brief_summary>
	<brief_title>A Safety Efficacy Study BCD-021 With Paclitaxel Carboplatin Compared Avastin With Paclitaxel Carboplatin Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Written inform consent ; Newly diagnose histologically cytologically confirm NSCLC exclude squamous NSCLC ( mixed cancer type classify accord prevalent cell type ) ; IIIb IV stage NSCLC ( TNM classification version 6 ) ; Age ≥ 18 year age ≤ 75 year ( inclusive ) ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 , ( decline within 2 week prior first dose investigational product ) ; Life expectancy 12 week moment randomization ; Presence least 1 measurable tumour size le 1 cm ( reveal CT slice thickness 5 mm ) , define modify Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( specifically , ascites , pleural , pericardial effusion , osteoblastic bone metastasis , carcinomatous lymphangitis lung lesion ; Patients able follow Protocol procedure ( accord Investigator 's assessment ) ; Patients must implement reliable contraceptive measure study treatment , start 4 week prior administration first dose investigational product 6 month last dose investigational product . This requirement apply participant undergone surgical sterilization , patient postmenopausal ( document ) past 2 year . Reliable contraceptive measure include two method contraception , include one barrier method Squamous NSCLC ; Proven coagulopathy , clinically significant hemorrhage past include nasal hemorrhage ; absolute neutrophil count &lt; 1500/mm3 ; Platelets &lt; 100 000/mm3 ; Hemoglobin &lt; 90 g/L ; Creatinine level ≥1.5 mg/dL ; Bilirubin level ≥1.5 × upper limit normal ( ULN ) ; Aspartateaminotransferase ( AST ) alanineaminotransferase ( ALT ) level ≥2.5 × ULN ( ≥5 × ULN patient liver metastasis ) ; Alkaline phosphatase level ≥5 × ULN ; Current therapeutic anticoagulation treatment , aspirin ( 325 mg/day ) , nonsteroidal antiinflammatory drug , antiplatelet agent protract treatment drug less 1 month enter study ; Uncontrolled hypertension comprise case arterial hypertension decrease blood pressure could achieve despite treatment combination 3 antihypertensive drug include one diuretic nonmedical correction method ( low salt diet , physical exercise ) ; Any previous anticancer therapy ( chemotherapy , radiation therapy , surgery etc . ) metastatic NSCLC ; Radiation hormone therapy within 21 day prior randomization ; Major surgery 28 day inclusion study ; Previous antiangiogenic therapy ; Hypersensitivity taxanes , platinum agent , recombinant murine protein , contrast agent , premedication agent specify Protocol ( dexamethasone , diphenhydramine , ranitidine ) excipients investigational product ; NSCLC metastases central nervous system exclude metastasis nonprogressing without glucocorticosteroids within 4 week inclusion trial ; Cardiovascular system pathology ( CHF stage IIIIV accord New York Heart Association ( NYHA ) classification ) ; Pregnancy lactation ; Conditions limit patient 's adherence Protocol requirement ( dementia , neurologic psychiatric disorder , drug addiction , alcoholism others ) ; Stage IIIV neuropathy accord Common Terminology Criteria Adverse Events ( CTCAE ) v.4.0 ; Simultaneous participation clinical trial , previous participation clinical trial within 30 day enter trial , previous participation trial ; Any concomitant cancer reveal within 5 year prior screen , except curatively treat intraductal carcinoma situ , curatively treated cervical carcinoma situ curatively treat basal cell squamous cell carcinoma ; Acute active chronic infection ; Hepatitis C virus , hepatitis B virus , HIV , syphilis infection ; Obstacles intravenous administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>